Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

March 7, 2024

Study Completion Date

March 7, 2024

Conditions

Healthy

Interventions

DRUG

BAP5191

Placebo

Trial Locations (1)

Universität Basel Departement Klinische Forschung Ambulantes Studienzentrum, Basel

All Listed Sponsors

collaborator

University Hospital, Basel, Switzerland

OTHER

collaborator

Swiss TPH, Basel, Switzerland

UNKNOWN

lead

Bacoba AG

INDUSTRY